Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab.

Date publication

décembre 2016

Journal

The American journal of gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Osterman MT, Sandborn WJ, Colombel JF, Peyrin-Biroulet L, Robinson AM, Zhou Q, Lewis JD

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/27670599

Résumé

Anti-tumor necrosis factor (TNF) drugs are commonly used to treat moderate-to-severe Crohn's disease (CD). Both the activity of CD and the concomitant immunosuppressants (corticosteroids and immunomodulators) used with anti-TNF drugs could increase the risk of infection. We determined the relative risk of serious and opportunistic infections associated with increasing disease activity and concomitant immunomodulators and corticosteroids in patients with CD treated with adalimumab.

Mots clés

Adalimumab, therapeutic use, Adrenal Cortex Hormones, therapeutic use, Adult, Anti-Inflammatory Agents, therapeutic use, Crohn Disease, drug therapy, Drug Therapy, Combination, Female, Herpes Zoster, epidemiology, Humans, Immunologic Factors, therapeutic use, Immunosuppressive Agents, therapeutic use, Male, Methotrexate, therapeutic use, Middle Aged, Multivariate Analysis, Opportunistic Infections, epidemiology, Proportional Hazards Models, Risk Factors, Severity of Illness Index, Young Adult

Référence

Am. J. Gastroenterol.. 2016 12;111(12):1806-1815